

**Date:** August 07, 2024

**Ref. No.:** KDL/SE/057/2024-25

<b>To,</b> <b>BSE Limited</b> <b>Corporate Relationship Department</b> 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 <b>Scrip Code:</b> 543328	<b>To,</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 <b>NSE Symbol:</b> KRSNAA
--	--

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015: - Revised Investor Presentation.**

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a revised copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2024.

Kindly note that, in the earlier intimation given by Company bearing number KDL/SE/053/2024-25 dated August 06, 2024, the amount of depreciation in note on page number 4 was erroneously mentioned as Rs. 397 million instead of Rs. 39.7 million. Apart from this, there is no change in the Presentation.

We regret the inconvenience caused.

Request you to take the same on your records.

Thanking you,  
Yours sincerely,

For Krsnaa Diagnostics Limited



**Sujoy Sudipta Bose**  
**Company Secretary & Compliance Officer**  
**Encl:** as above

# Q1FY2025 Result Presentation

*One of INDIA'S LARGEST Differentiated Diagnostic Service Provider*



# Q1FY2025 Performance

# Krsnaa Diagnostics Q1FY25 – Operations at a Glance



## Bharat ka Bharosemand Diagnostics

**India's 1<sup>st</sup>**  
CAP Accreditation  
in Govt. Hospital

**India's 1<sup>st</sup>**  
NABH Accredited Tele  
radiology HUB

### Radiology

**168**  
CT/MRI Centres

**1,443**  
Tele-Reporting  
Centre

### Pathology

**120**  
Processing lab

**2,270**  
Collection  
Centre

**NABH**  
**22**  
Accredited  
centres

**NABL**  
**23**  
Accredited  
centres



### Presence In India

**150+**  
District Location

**17**  
States & Union  
Territories

### Patient served

**40Mn+**  
Last 3 years

### Doctors Associated

**500+**

### Strengths

**~ 1.5 Lakh**  
CT & MRI Scans per  
month

**~ 6 lakhs**  
X-rays per month

### CAGR

**24%**  
Last 5 years

### ICRA Rating

**A**  
Stable

### Bid Win Ratio

**75%+**

# Krsnaa Diagnostics Q1FY25 – Financials at a Glance



In mn

Maintaining Growth Momentum: Achieving 22% YoY Revenue Growth, 39% YoY EBITDA Strengthening & 22% YoY improvement in PAT, on account of network expansion and enhanced operational efficiency






Note: EBIDTA & EBIDTA Margin are before CSR & ESOP, Diluted EPS in INR

# Q1FY25 EBITDA Analysis



In mn

EBITDA Margins Before CSR and ESOP



*Note: Considering the nature of business, financial performance is best evaluated on an annualized basis.*

# Financial Performance



In mn

Particulars	Q1 FY 25		Q1 FY 24		Q4 FY 24		FY 24		FY 23	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
Revenue from operations	1,702		1,396		1,663		6,196		4,871	
<b>Expenses</b>										
Cost of Material Consumed	429	25%	278	20%	430	26%	1,410	23%	742	15%
Employee benefits expense	320	19%	228	16%	324	19%	1,106	18%	739	15%
Fees to hospitals and others	123	7%	174	13%	94	6%	655	11%	812	17%
Other expenses	388	23%	398	29%	374	22%	1,560	25%	1,338	27%
<b>Total Expenses</b>	<b>1,261</b>	<b>74%</b>	<b>1,077</b>	<b>77%</b>	<b>1,222</b>	<b>73%</b>	<b>4,731</b>	<b>76%</b>	<b>3,631</b>	<b>75%</b>
<b>EBITDA Before CSR &amp; ESOP</b>	<b>442</b>	<b>26%</b>	<b>319</b>	<b>23%</b>	<b>441</b>	<b>27%</b>	<b>1,465</b>	<b>24%</b>	<b>1240</b>	<b>25%</b>
CSR and ESOP	15	1%	5	0%	4	0%	23	0%	17	0%
<b>EBITDA</b>	<b>427</b>	<b>25%</b>	<b>314</b>	<b>23%</b>	<b>437</b>	<b>26%</b>	<b>1,442</b>	<b>23%</b>	<b>1223</b>	<b>25%</b>
Less: Finance costs	53	3%	20	1%	73	4%	165	3%	77	2%
Less: Depreciation	215	13%	157	11%	181	11%	745	12%	538	11%
Add: Other income	73	4%	42	3%	43	3%	168	3%	194	4%
<b>PBT</b>	<b>232</b>	<b>14%</b>	<b>179</b>	<b>13%</b>	<b>226</b>	<b>14%</b>	<b>700</b>	<b>11%</b>	<b>802</b>	<b>16%</b>
Tax	53	3%	32	2%	39	2%	132	2%	181	4%
<b>PAT</b>	<b>179</b>	<b>11%</b>	<b>146</b>	<b>11%</b>	<b>187</b>	<b>11%</b>	<b>568</b>	<b>9%</b>	<b>621</b>	<b>13%</b>

Note: The PAT for Q4FY24 after adjusting the depreciation benefit of Rs. 39.7 million due to change in accounting estimates for the entire last year which was accounted for in Q4 FY24, would have been Rs. 158 million, **resulting in PAT growing by 14% in Q1FY25 as compared to Q4FY24 demonstrating a healthy growth**



## Operational Highlights




# Only Company with Pan India Presence in Both Radiology and Pathology



\*Under Implementation  
 \*\* The USG, Dexa, Mammography and TMT Centres are not marked in this map.

## Well Diversified Regional Revenue Mix



### High Headroom to Grow

- Highest penetration across districts with presence in 150+ out of 700+ districts; still large underpenetrated market
- Government continuous focus on improving healthcare in India and looking to partner under PPP model
- Krsnaa is already present in most of the tier I, II, III and rural areas. Krsnaa plans to leverage its extensive presence for growth



## Recent Developments

# Project under Implementation



## Radiology Centres Under Implementation

	Total Centres	Operational	Under Implementation
Uttar Pradesh	8	5	3
Delhi	1	1	-
DMC	1	-	1
Mira Bhayandar	1	-	1
Rajasthan	1	-	1
Maharashtra	73	32	41
Madhya Pradesh	5	-	5
<b>Total</b>	<b>90</b>	<b>38</b>	<b>52</b>

## Pathology Centres Under Implementation

	Total Centres	Operational	Under Implementation
DMC	1	-	1
BMC CC	600	473	127
Odisha CC	600	-	600
Mira Bhayandar	1	-	1
Assam	10	9	1
Assam CC	1,256	387	869
<b>Total</b>	<b>2,468</b>	<b>869</b>	<b>1,599</b>


One of the only company in India to have 220 CT / MRI centers installed & operational / under installation




## Way Forward



We aim to sustain the upward trajectory of our Revenue and PAT CAGR by utilizing our existing facilities and seizing opportunities in untapped markets



*Note: Our growth strategy is well defined and allows us to achieve steady state growth irrespective of dependence on individual projects like Rajasthan*





This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

**Krsnaa Diagnostics**

**Vivek Jain, Investor Relation Head**

[head.investor@krsnaa.in](mailto:head.investor@krsnaa.in)

Contact: +91 74107 00645